131 related articles for article (PubMed ID: 21748635)
1. A nanoparticle for tumor targeted delivery of oligomers.
Liu X; Wang Y; Hnatowich DJ
Methods Mol Biol; 2011; 764():91-105. PubMed ID: 21748635
[TBL] [Abstract][Full Text] [Related]
2. Cell studies of a three-component antisense MORF/tat/Herceptin nanoparticle designed for improved tumor delivery.
Liu X; Wang Y; Nakamura K; Kubo A; Hnatowich DJ
Cancer Gene Ther; 2008 Feb; 15(2):126-32. PubMed ID: 18084241
[TBL] [Abstract][Full Text] [Related]
3. Simplified preparation via streptavidin of antisense oligomers/carriers nanoparticles showing improved cellular delivery in culture.
Wang Y; Nakamura K; Liu X; Kitamura N; Kubo A; Hnatowich DJ
Bioconjug Chem; 2007; 18(4):1338-43. PubMed ID: 17605463
[TBL] [Abstract][Full Text] [Related]
4. Auger-mediated cytotoxicity of cancer cells in culture by an 125I-antisense oligomer delivered as a three-component streptavidin nanoparticle.
Liu X; Nakamura K; Wang Y; Cheng D; Liang M; Xiao N; Chen L; Rusckowski M; Hnatowich DJ
J Biomed Nanotechnol; 2010 Apr; 6(2):153-7. PubMed ID: 20738069
[TBL] [Abstract][Full Text] [Related]
5. Auger radiation-induced, antisense-mediated cytotoxicity of tumor cells using a 3-component streptavidin-delivery nanoparticle with 111In.
Liu X; Wang Y; Nakamura K; Kawauchi S; Akalin A; Cheng D; Chen L; Rusckowski M; Hnatowich DJ
J Nucl Med; 2009 Apr; 50(4):582-90. PubMed ID: 19289423
[TBL] [Abstract][Full Text] [Related]
6. Tumor delivery of antisense oligomer using trastuzumab within a streptavidin nanoparticle.
Wang Y; Liu X; Chen L; Cheng D; Rusckowski M; Hnatowich DJ
Eur J Nucl Med Mol Imaging; 2009 Dec; 36(12):1977-86. PubMed ID: 19572130
[TBL] [Abstract][Full Text] [Related]
7. Comparing the intracellular fate of components within a noncovalent streptavidin nanoparticle with covalent conjugation.
Liu Y; Cheng D; Liu X; Liu G; Dou S; Xiao N; Chen L; Rusckowski M; Hnatowich DJ
Nucl Med Biol; 2012 Jan; 39(1):101-7. PubMed ID: 21958854
[TBL] [Abstract][Full Text] [Related]
8. In vivo delivery of antisense MORF oligomer by MORF/carrier streptavidin nanoparticles.
Wang Y; Liu X; Nakamura K; Chen L; Rusckowski M; Hnatowich DJ
Cancer Biother Radiopharm; 2009 Oct; 24(5):573-8. PubMed ID: 19877887
[TBL] [Abstract][Full Text] [Related]
9. Her2/neu small interfering RNA delivered in culture by a streptavidin nanoparticle.
Liu X; Nakamura K; Cheng D; Peng C; Xiao N; Liu Y; Chen L; Rusckowski M; Hnatowich DJ
Curr Drug Deliv; 2012 Jul; 9(4):431-6. PubMed ID: 22520071
[TBL] [Abstract][Full Text] [Related]
10. Cell culture and xenograft-bearing animal studies of radiolabeled antisense DNA carrier nanoparticles with streptavidin as a linker.
Nakamura K; Wang Y; Liu X; Kubo A; Hnatowich DJ
J Nucl Med; 2007 Nov; 48(11):1845-52. PubMed ID: 17978353
[TBL] [Abstract][Full Text] [Related]
11. A non-covalent peptide-based strategy for ex vivo and in vivo oligonucleotide delivery.
Crombez L; Morris MC; Heitz F; Divita G
Methods Mol Biol; 2011; 764():59-73. PubMed ID: 21748633
[TBL] [Abstract][Full Text] [Related]
12. Selective inhibition of ErbB2-overexpressing breast cancer in vivo by a novel TAT-based ErbB2-targeting signal transducers and activators of transcription 3-blocking peptide.
Tan M; Lan KH; Yao J; Lu CH; Sun M; Neal CL; Lu J; Yu D
Cancer Res; 2006 Apr; 66(7):3764-72. PubMed ID: 16585203
[TBL] [Abstract][Full Text] [Related]
13. Factors determining the efficacy of nuclear delivery of antisense oligonucleotides by gold nanoparticles.
Liu Y; Franzen S
Bioconjug Chem; 2008 May; 19(5):1009-16. PubMed ID: 18393455
[TBL] [Abstract][Full Text] [Related]
14. Targeting HER2+ breast cancer cells: lysosomal accumulation of anti-HER2 antibodies is influenced by antibody binding site and conjugation to polymeric nanoparticles.
Owen SC; Patel N; Logie J; Pan G; Persson H; Moffat J; Sidhu SS; Shoichet MS
J Control Release; 2013 Dec; 172(2):395-404. PubMed ID: 23880472
[TBL] [Abstract][Full Text] [Related]
15. Targeting trastuzumab-resistant breast cancer cells with a lentivirus engineered to bind antibodies that recognize HER-2.
Zhang KX; Kim C; Chow E; Chen IS; Jia W; Rennie PS
Breast Cancer Res Treat; 2011 Jan; 125(1):89-97. PubMed ID: 20232140
[TBL] [Abstract][Full Text] [Related]
16. Cell-penetrating peptides and peptide nucleic acid-coupled MRI contrast agents: evaluation of cellular delivery and target binding.
Mishra R; Su W; Pohmann R; Pfeuffer J; Sauer MG; Ugurbil K; Engelmann J
Bioconjug Chem; 2009 Oct; 20(10):1860-8. PubMed ID: 19788302
[TBL] [Abstract][Full Text] [Related]
17. The co-delivery of paclitaxel and Herceptin using cationic micellar nanoparticles.
Lee AL; Wang Y; Cheng HY; Pervaiz S; Yang YY
Biomaterials; 2009 Feb; 30(5):919-27. PubMed ID: 19042015
[TBL] [Abstract][Full Text] [Related]
18. Five-step process for screening antisense compounds for efficacy: gene target IL-12Rb2.
Marshall NB; Hauck LL; Mourich DV
Methods Mol Biol; 2011; 764():153-68. PubMed ID: 21748639
[TBL] [Abstract][Full Text] [Related]
19. Targeting human epidermal growth factor receptor 2 by a cell-penetrating peptide-affibody bioconjugate.
Govindarajan S; Sivakumar J; Garimidi P; Rangaraj N; Kumar JM; Rao NM; Gopal V
Biomaterials; 2012 Mar; 33(8):2570-82. PubMed ID: 22192536
[TBL] [Abstract][Full Text] [Related]
20. Multifunctional poly(D,L-lactide-co-glycolide)/montmorillonite (PLGA/MMT) nanoparticles decorated by Trastuzumab for targeted chemotherapy of breast cancer.
Sun B; Ranganathan B; Feng SS
Biomaterials; 2008 Feb; 29(4):475-86. PubMed ID: 17953985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
